Eli Lilly Surges 5% on Zepbound Demand, Uber Beats by 44%

Everyone is glued to the Strait of Hormuz news alerts and oil price charts, which means the market is almost sleeping on two of the cleanest earnings beats of the week. Let's fix that.

$LLY surged more than 5% after Eli Lilly reported stronger-than-expected second quarter demand for Zepbound, its weight loss drug, alongside solid diabetes medication sales. This was not a one-product fluke. The GLP-1 category is compounding, and Lilly keeps proving it is the category leader. Analysts tracking the CNBC coverage noted the beat was broad-based across revenue and profit lines, not just a cost-cutting story. Meanwhile, $CVS raised its full-year profit outlook on better-than-expected medical costs in its Aetna insurance unit and cut the price of virtual weight management visits from $49 to $29, a move that looks a lot like CVS planting its flag in the GLP-1 services ecosystem before the competition realizes what is happening.

Over on the ride-share side, $UBER delivered its first earnings beat in three quarters, posting $1.17 per share against estimates of $0.81, a 44-cent beat that is not a rounding error. Gross bookings hit $58 billion, topping estimates, and CEO Dara Khosrowshahi explicitly said there are no signs of consumer trade-down behavior, no smaller basket sizes, and driver earnings are holding up. The revenue miss ($14.19B vs. $14.24B expected) was attributed to a UK accounting change, not demand weakness. That is the kind of footnote that gets punished in a risk-off tape but rewarded in a rally.

Zooming out, BNY Wealth CIO Alicia Lavine made a point on Bloomberg Surveillance worth repeating: missing just the best month of any given year costs roughly 500 basis points of annual performance. She set an S&P 500 target of 8,000 with upside risk, citing 30% forward earnings growth and tech trading at its lowest relative valuation in 15 years at roughly 20x forward earnings, cheaper than non-tech. The macro fog from the Iran war is real, but it is obscuring some genuinely strong fundamental signals underneath.

The sentiment picture on YouTube and financial social channels right now is split: macro traders are watching every Hormuz headline, while earnings-focused investors are quietly accumulating the names that just printed clean numbers. That divergence rarely lasts long, and when it closes, it tends to close in favor of the fundamentals crowd.

The market is doing two things at once this week, and the less glamorous one might actually be the more profitable one to watch.